CSL Behring News)

Global Newsroom

Recent News Releases

 

Latest CSL News

Latest CSL News

UQ, CEPI and CSL partner for COVID-19
05 Jun 2020

• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate
• CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate
• A vaccine is anticipated to be available in 2021 if clinical trials are successful

2021 CSL Centenary Fellowships
01 Jun 2020

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

CSL’s Global Role in Battling COVID-19
07 May 2020

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

Development of COVID-19 immunoglobulin commences
06 May 2020

Plasma-derived therapeutic with potential to treat serious complications of COVID-19.

COVID-19 Update
04 May 2020

CSL continues to provide medicines to patients around the world.

CSL Behring and SAB Biotherapeutics Join Forces
08 Apr 2020

King of Prussia, Pa. and Sioux Falls, S.D.

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer

Collaborating on Potential COVID-19 Therapy
06 Apr 2020

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Our Offer To Help Battle Coronavirus
18 Mar 2020

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

CSL Media Statement on Coronavirus
12 Feb 2020

CSL Limited's statement on Coronavirus

CSL Ranks Among Best Employers for Diversity
22 Jan 2020

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.

CSL at J.P. Morgan's 2020 Healthcare Conference
09 Jan 2020

Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.

CSL Continues to Advance R&D Capabilities
04 Dec 2019

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.

CSL Media Statement
18 Oct 2019

CSL statement in response to media reports on case against Joseph Chiao

CSL Limited Celebrates 25 Years on the ASX
14 Oct 2019

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

$2.5 million CSL Centenary Fellowships announced
10 Oct 2019

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

CSL to Move Global Headquarters
07 Aug 2019

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination

CSL Names Paul McKenzie as Chief Operating Officer
15 May 2019

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

CSL Renews Partnership with NYSF
15 Mar 2019

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long STEM literacy.

Nancy Millis building opens at Bio21 Institute
14 Dec 2018

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, incorporating CSL’s Global Hub for Research and Translational Medicine.

Developments in cell-based vaccine technology
05 Dec 2018

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

News archive 2016 pdf
News archive 2015 pdf
News archive 2014 pdf
News archive 2013 pdf